TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15132403
Drug: Ezetimibe coadministered
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10, 20, 40, or 80 mg/d)
Study: 15132403
Drug: Ezetimibe coadministered
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10 mg/d)
Study: 15132403
Drug: Ezetimibe/simvastatin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin and simvastatin monotherapy
Study: 3723999
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 0.1 ml human diploid cell vaccine (HDCV)
Study: 3723999
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 0.1 ml human diploid cell vaccine (HDCV)
Study: 3723999
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of 0.1 ml human diploid cell vaccine (HDCV)
Study: 3723999
Drug: 8 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 doses of 0.1 ml human diploid cell vaccine (HDCV)
Study: 30322724
Drug: Single-course clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-course clindamycin (300 mg twice-daily for 4 days)
Study: 30322724
Drug: Triple-course clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-course clindamycin (300 mg twice-daily for 4 days)
Study: 27385272
Drug: Sleep education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep education program with self-help treatment
Study: 3055791
Drug: Bupivacaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (2 mg/kg)
Study: 18188762
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (100 microg of purified 3'-aminomethylnicotine conjugated to detoxified Pseudomonas aeruginosa r-exoprotein A)
Study: 18188762
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (fourth dose at day 182)
Study: 15879167
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive (OC) users during luteal phase (Lut)
Study: 15879167
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of Oral Contraceptives (NOC)
Study: 15879167
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive (OC) users during follicular phase (Fol)
Study: 7540996
Drug: Escalating dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dosage of interferon alfa (starting at 3 million units, increasing to 5 million units at 8 weeks for nonresponders, and to 10 million units 8 weeks later for persistent nonresponders)
Study: 7540996
Drug: Constant dosage
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant dosage of interferon alfa (3 million units three times weekly for 24 weeks)
Study: 2212144
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation A of 2.5% hydrocortisone cream
Study: 2212144
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation B of 2.5% hydrocortisone cream
Study: 648169
Drug: Griseofulvin every
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin every other day (5 mg/lb, max 1 gm/day)
Study: 648169
Drug: Griseofulvin twice
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin twice a week (5 mg/lb, max 1 gm/day)
Study: 30850011
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tamoxifen
Study: 30850011
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tamoxifen
Study: 31940324
Drug: Anti-viral treatment
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-viral treatment
Study: 20391505
Drug: Experimental knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental knee pain (hypertonic saline injections 0.75 ml)
Study: 10601914
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (1 mg micronized 17beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and 2 mg 17beta‐estradiol combined with 10 mg dydrogesterone thereafter for a period of 3 months)
Study: 2245833
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) and intrauterine insemination (IUI)
Study: 7449382
Drug: TGLVP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGLVP (0.5 mg and 1 mg)
Study: 7449382
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug injection)
Study: 6466531
Drug: Suxamethonium 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 10 mg pretreatment followed by 1 mg/kg suxamethonium
Study: 31714912
Drug: Testosterone (Tostran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (Tostran 2% gel)
Study: 29183257
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.2 g.kg-1 BM)
Study: 29183257
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g.kg-1 BM)
Study: 29183257
Drug: Placebo (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.07 g.kg-1 BM sodium chloride)
Study: 22378800
Drug: Probiotic preparation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation, specific dosage and duration not mentioned
Study: 17584828
Drug: Mifepristone (RU486),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (RU486), single dose administered during the mid-secretory phase.
Study: 10449105
Drug: anti-alpha4 integrin
Normalized name: Anti-alpha4 integrin
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anti-alpha4 integrin antibody (natalizumab; Antegren)
Study: 7840362
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day of oral dexamethasone for 4 days
Study: 525066
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg piroxicam daily for two weeks (7 patients)
Study: 525066
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indomethacin tid for two weeks (9 patients)
Study: 525066
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects due to trial treatment
Study: 25601604
Drug: Caffeine 100
Normalized name: caffeine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 100 mg encapsulated, taken 2 hours prior to intercourse for 3 weeks
Study: 24503140
Drug: Pitavastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (4 mg) plus Eicosapentaenoic acid (EPA) (1800 mg)
Study: 17478464
Drug: Lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400 mg once daily (o.d.)
Study: 17478464
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg three times daily (t.i.d.)
Study: 8638525
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of organic nitrates
Study: 8233745
Drug: DTP-HbOC combined
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-HbOC combined vaccine (0.5 mL injection)
Study: 8233745
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTP and HbOC (0.5 mL each in separate legs)
Study: 2992116
Drug: Suloctidil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suloctidil (200 mg t.i.d.)
Study: 29231546
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group with acupuncture and huazhuo jiedu jiangni decoction
Study: 29231546
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group with omeprazole (20 mg, twice a day)
Study: 29231546
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine group (decoction only)
Study: 26243048
Drug: Targeted percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted percutaneous microwave ablation combined with mediastinal radiotherapy with or without chemotherapy (ablation group)
Study: 26243048
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with or without chemotherapy (RT group)
Study: 23390005
Drug: Coping Cat
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping Cat individual cognitive‐behavioral therapy (CBT)
Study: 23390005
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management with sertraline (SRT)
Study: 23390005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and medication management
Study: 23390005
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment conditions (CBT, SRT, COMB, PBO)
Study: 21228609
Drug: Mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30 mg/day
Study: 18854204
Drug: 1,25(OH)2D3 analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 analog BXL746 (acute administration)
Study: 18854204
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of BXL746
Study: 18854204
Drug: 1,25(OH)2D3 (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 (chronic administration)
Study: 17135584
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus pioglitazone (45 mg daily)
Study: 17132769
Drug: No daily
Normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No daily sunscreen use
Study: 8180301
Drug: Daily NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily NSAID usage
Study: 28925324
Drug: Multi-layer compression
Normalized name: bandages, multi-layer compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-layer compression therapy (MLCT)
Study: 28925324
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with Cool Pack (CG)
Study: 23288353
Drug: Mean arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure (MAP) target of 80-85 mm Hg for 30 min (using norepinephrine infusion)
Study: 20709569
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (midazolam and opioids)
Study: 19579987
Drug: Metoprolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (1 mg kg(‐1) daily)
Study: 14963657
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (initial dosages of 60-100 mg for 7-14 days, followed by dose reduction over several months)
Study: 14963657
Drug: Intravenous corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous corticosteroids (initial dosages of 500-1,000 mg methylprednisolone at distinct intervals)
Study: 11844203
Drug: Vaginal misoprostol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal misoprostol, 50 microg 6‐hourly
Study: 11844203
Drug: Dinoprostone gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone gel, 1‐2 mg 6‐hourly
Study: 319204
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg naloxone i.v.
Study: 30414387
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg followed by 90 mg twice daily (ONSET/OFFSET study)
Study: 30414387
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg twice daily (PEGASUS-TIMI 54 substudy)
Study: 30414387
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily (PEGASUS-TIMI 54 substudy)
Study: 30414387
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg followed by 75 mg once daily (ONSET/OFFSET study)
Study: 16755160
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (5 mg oral daily or 5 mg every other day)
Study: 9055717
Drug: Community thrombolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community thrombolysis (intravenous anistreplase administered by general practitioners)
Study: 9055717
Drug: Hospital thrombolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital thrombolysis (intravenous anistreplase administered by secondary care clinicians)
Study: 30621479
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L polyethylene glycol with ascorbic acid plus 2 mg prucalopride (1LP/AP)
Study: 30621479
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L polyethylene glycol with ascorbic acid (2LP/A)
Study: 22843897
Drug: Gentle strength
Normalized name: Ex-Lax Gentle Strength
DrugBank: Sennosides (DB11365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentle strength training (lifting standardized weights weekly at 50% of h1RM)
Study: 21092037
Drug: Transfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion therapy after cardiopulmonary bypass with fibrinogen administration combined with traditional transfusion, guided by TEG (Group F)
Study: 12750062
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA; 3 mg/kg over 5 min)
Study: 12750062
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA; 6 mg/kg over 5 min)
Study: 12750062
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA; 3 mg/kg and 6 mg/kg)
Study: 1642662
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral tiludronate
Study: 1642662
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral tiludronate
Study: 1642662
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral tiludronate
Study: 1642662
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral tiludronate
Study: 31403974
Drug: Dexmedetomidine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (low infusion rate: 0.5 μg · kg · h; moderate infusion rate: 1.5 μg · kg · h)
Study: 31403974
Drug: Propofol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (low infusion rate: 42 μg · kg · min; moderate infusion rate: 83 μg · kg · min)
Study: 31403974
Drug: Dexmedetomidine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (low infusion rate)
Study: 31403974
Drug: Propofol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (low infusion rate)
Study: 31403974
Drug: Dexmedetomidine (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (moderate infusion rate)
Study: 31403974
Drug: Propofol (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (moderate infusion rate)
Study: 31403974
Drug: Dexmedetomidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine and Propofol (both infusion rates)
Study: 10804490
Drug: Suture closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture closure of the subcutaneous tissue
Study: 24738117
Drug: Non-closure of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-closure of the subcutaneous tissue
Study: 21236699
Drug: Lipid-lowering medications
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering medications (LLMs) including statins
Study: 7945126
Drug: cinnarizine 50
Normalized name: cinnarizine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinnarizine 50 mg
Study: 7945126
Drug: cinnarizine 25
Normalized name: cinnarizine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinnarizine 25 mg
Study: 2855116
Drug: Alcohol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.2 g/kg)
Study: 2855116
Drug: Alcohol (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0 g/kg)
Study: 31788849
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg rectal diclofenac administered 30 minutes before ERCP
Study: 25953193
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements (Lactobacillus reuteri)
Study: 25953193
Drug: Placebo (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (topical oil application and lozenges)
Study: 24756186
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg oral)
Study: 8859725
Drug: THERATOPE STn‐KLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: THERATOPE STn‐KLH cancer vaccine emulsified in DETOX adjuvant
Study: 8859725
Drug: Low‐dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose intravenous cyclophosphamide before ASI
Study: 8859725
Drug: Anti‐KLH antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐KLH antibody titers
Study: 1516489
Drug: Intermittent glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent glyburide therapy (2 weeks on, 2 weeks off)
Study: 1516489
Drug: Continuous glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glyburide therapy
Study: 26540163
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention combining telemonitoring, medication management, self-management support, and depression management.
Study: 24910934
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA; onabotulinumtoxinA) injections; Female participants received 29 units; Male participants received 39 units
Study: 24910934
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA; onabotulinumtoxinA) injections
Study: 20368402
Drug: Amodiaquine (AQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine (AQ) and Artesunate (AS) combination therapy
Study: 15996811
Drug: Doxazosin gastrointestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin gastrointestinal therapeutic system (DOX GITS) 4 mg/d
Study: 14507273
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (Ca) 1 g
Study: 14507273
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (Ca) 2 g
Study: 14507273
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (Ca) 4 g
Study: 14507273
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (Ca)
Study: 8644427
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy including 5-fluorouracil and leucovorin
Study: 8644427
Drug: Fluorouracil in
Normalized name: fluorouracil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil in combination with levamisole or leucovorin
Study: 1998792
Drug: Stopping the
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping the combined oral contraceptive pill
Study: 6147193
Drug: SCH 399
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 399 syrup (combination of azatadine maleate, pseudoephedrine sulfate, and dextromethorphan hydrobromide)
Study: 6147193
Drug: Expectorant containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectorant containing diphenhydramine hydrochloride
Study: 14579028
Drug: Nonoperative therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative therapy, including modification of sports and recreational activities
Study: 10862585
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (n = 39)
Study: 10862585
Drug: Oral flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flecainide (n = 40)
Study: 1420057
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of Diamox Sustets (acetazolamide) 1 hour preoperatively
Study: 1420057
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of acetazolamide and acetylcholine
Study: 31063198
Drug: Infant oral
Normalized name: Dolono Infant Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant oral microbiome
Study: 30092157
Drug: 1000 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU/day vitamin D (cholecalciferol, Calcirol® sachet) administered as a stat dose of 90,000 IU every three months.